SWISS Pavilion at BioJapan 2026

CARBOGEN AMCIS supports the pharmaceutical and biopharmaceutical industries at every stage of drug development, from contract process research and development to the supply of Active Pharmaceutical Ingredients (APIs) and drug products for preclinical studies, clinical trials and commercial use.

The company also manufactures high-quality Cholesterol and Vitamin D analog products at its facility in the Netherlands, supplying a range of global markets. Backed by a passion for great science, timely communication and total commitment to each partner’s project, CARBOGEN AMCIS aims to become the partner of choice for development and manufacturing — helping customers move their projects faster to market.

DINAMIQS, a subsidiary of Siegfried Holding AG, is a pure-play viral vector CDMO focused on adeno-associated virus (AAV) and lentiviral vectors (LVV) for cell and gene therapies. The company offers integrated upstream and downstream development — including genome engineering and process optimization for novel capsids — with rapid scale-up to clinical GMP production in 7–9 months. Its scalable, suspension-based platform relies on single-use, fully closed systems for reproducibility, quality and commercial readiness.

DINAMIQS supports client-owned or third-party cell lines without vendor lock-in, offers a transparent sublicensing model for flexible process transfer, and provides comprehensive in-house analytical development, QC and stability testing from preclinical through clinical stages. Headquartered in Zurich with a new modular GMP facility at Biotechnopark Schlieren, DINAMIQS combines Swiss quality with global CDMO expertise, supplying clinical materials across Europe, the United States and APAC.

GALSER is a Swiss clinical research and regulatory partner guiding biotech and pharma sponsors from early development to post-market studies. By bridging clinical operations, regulatory expertise, and Swiss marketing authorization and distribution access, GALSER helps partners move their programs efficiently from trials to market.

GlioCART is developing a first-in-class, dual-action CAR-T cell therapy for glioblastoma — one of the deadliest brain cancers, with little therapeutic progress in the past 20 years and a multi-billion-dollar market expected to double within a decade. The therapy is designed to overcome key barriers of conventional CAR-T approaches in solid tumors by combining direct tumor killing with local reprogramming of the immunosuppressive tumor microenvironment.

Its lead candidate, GlioCART-01, targets EGFRvIII-positive tumor cells and reprograms tumor-associated macrophages to eliminate antigen-negative bystander tumor cells. Following strong preclinical results — including complete tumor regression and durable survival — GlioCART is preparing GMP manufacturing and its first-in-human trial, aiming to offer a new therapeutic option with the potential for durable responses in glioblastoma.

Lonza’s Personalized Medicine business unit is enabling the future of personalized cell therapy and bringing it to the clinic. The Lonza Cocoon® Platform is an automated, closed and highly flexible cell therapy manufacturing system designed for patient-scale (autologous) cell and gene therapies.

ten23 health is a Swiss CDMO specializing in sterile injectable drug products, providing integrated support from preclinical and early-stage development through commercial manufacturing — including formulation development, analytics, aseptic filling and regulatory support. Its expertise covers pre-filled syringes, vials, cartridges, intravitreal formulations, high-viscosity biologics and subcutaneous injectable products requiring advanced technical capabilities. By applying a Quality by Design (QbD) approach from the earliest stages of development, ten23 health designs formulations and processes with future commercial production in mind — minimizing development risks, improving manufacturability and accelerating the path to clinical and commercial success. Supported by state-of-the-art facilities compliant with EU GMP Annex 1 and a highly experienced team, ten23 health welcomes the opportunity to discuss development and manufacturing challenges, including dosage form conversion for lifecycle management.

Business development in Japan & APAC for this Swiss CDMO dedicated to parenteral drug products.

Ymmunobio AG is a preclinical-stage biotechnology company developing first-in-class assets for the treatment of solid tumors. Its YB-800 Theranostics Platform targets a novel, first-in-class tumor marker for targeted cancer therapy, and comprises two antibody-drug conjugates (ADCs), two radiopharmaceuticals, two bispecific antibodies with an aCD3 component, one SPECT/PET diagnostic scan, and a liquid biopsy diagnostic developed in collaboration with EVIIVE.

Looking for:

• Companies specializing in ADCs
• Companies specializing in radiopharmaceuticals
• Companies specializing in bispecific antibodies with an aCD3 component
• Companies specializing in tumor marker diagnostics

The Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, it works to secure favorable framework conditions and facilitate access to talent, novel technologies and financial resources.

Switzerland is Europe’s leading life-sciences ecosystem, the world’s most innovative country for 15 consecutive years, and a powerhouse for startups.

Switzerland Innovation helps Japanese pharma and biotech companies access Switzerland’s dynamic innovation ecosystem by connecting them with Swiss partners, including the Swiss Biotech Association, and by facilitating investment and R&D collaborations. It also organizes tailor-made fact-finding missions to Switzerland and an annual Japanese delegation to Swiss Biotech Day.

Swissnex is the global network connecting Switzerland and the world in education, research and innovation. Its mission is to support the outreach and active engagement of its partners in the international exchange of knowledge, ideas and talent — strengthening Switzerland’s profile as a world-leading innovation hotspot.

Swissnex helps Swiss startups go global through equity-free, tailor-made programs and internationalization camps, drawing on a wide-ranging ecosystem of creative activities across education, research and innovation — encompassing foresight, technology and trend scouting.

Startups supported by Swissnex at BioJapan:

Annaida Technologies has re-engineered magnetic resonance spectroscopy to operate at the microscale, opening a new window into the chemistry of living organisms and intact biological samples.

Its flagship platform, microMRS-MED, applies advanced microscale Magnetic Resonance Spectroscopy (MRS) to assisted reproduction, aiming to improve clinical decision-making, increase treatment success rates, and reduce the physical and emotional burden of infertility. Beyond the clinic, Annaida’s technology supports researchers across the life sciences with precise, microscale analysis of cellular metabolism and biological function.

Founded in 2017, Curio Biotech is a specialized in vitro Contract Research Organization (CRO) with expertise in primary human cell culture, advanced 3D tissue-engineered models, and ex vivo systems. Its platforms support screening, efficacy, mechanism-of-action, safety, DMPK, and biomarker discovery — enabling seamless progression from early discovery to translational milestones.

By centering its science on primary human cells and tissues, Curio Biotech delivers data closer to clinical reality, derisking programs early and reducing late-stage failures at predictable budgets. The company is fully aligned with 3R principles, New Approach Methodologies (NAMs), and the U.S. FDA Modernization Act 2.0, and has delivered projects across dermatology, aging, inflammation, immuno-oncology, vascular biology, autoimmune disease, metabolism, and regenerative biology for clients spanning three continents.

Magnes AG is an ETH Zurich spin-off headquartered in Zurich, specializing in AI-powered human movement analysis through wearable sensors and vibrotactile feedback technology.

Since launching its first product in 2021, Magnes has continuously refined its technology to deliver better outcomes for consumers and clinicians alike, pushing the boundaries of what’s possible in gait analysis.

REM Analytics offers precision microbiome testing — from clinical diagnostics to microbiome research to agricultural applications — identifying and quantifying individual microbial species.

Where closely related microorganisms have different functions or clinical impacts, REM Analytics’ measurements reveal the distinctions that matter.

Synendos is a clinical-stage neuroscience company developing potentially breakthrough, safe and effective therapies for neuropsychiatric and neurological disorders through modulation of a novel drug target in the endocannabinoid system — enabling restoration of the brain’s natural functioning.

PRIMA Genetics, a future spin-off from the University of Zurich, Switzerland, is developing a rapid diagnostic platform that detects clinically relevant genetic variations within one hour to support personalized medicine in both acute and routine care. While the assay kit is being validated, the instrument and software are still in the concept and development phase.

The company’s first focus is stroke and cardiovascular treatment pharmacogenetics, with a broader long-term vision to expand into companion diagnostics and antibiotic selection. PRIMA Genetics is seeking expert insights to better understand how its project might align with the needs of the Japanese market.